Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do vaccines work as well in people with weak immune systems? new study investigates

NCT ID NCT04952766

Knowledge-focused Sponsor: Centre Hospitalier Régional d'Orléans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutralize the virus over six months. The goal was to understand if immunocompromised people get the same protection from the vaccine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BNT162b2 (Pfizer-BioNTech COVID-19 vaccine)
What this could lead to
If successful, this study could show how well the COVID-19 vaccine protects immunocompromised people, helping tailor vaccination strategies for them.
What could go wrong
This is a completed observational study, not a treatment trial. It measures immune response but does not test a new therapy, so it won't directly change care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

196 people

The number who actually took part.

Started

Mar 2021

Finished

Feb 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult volunteers to be vaccinated with the ComirnatyTM vaccine and to participate in the study, belonging to one of the following groups: * Group of immunocompromised (15 participants per immunosuppression subgroup): * Kidney transplant * Extracorporeal dialysis * Solid cancer under chemotherapy and / or radiotherapy * Myeloma under chemotherapy * Hematologic malignancies under chemotherapy * Diseases treated with anti CD20 (or patients not treated at the time of the vaccine but who will be immediately after) * Multiple sclerosis under anti CD20 (or patients not treated at the time of the vaccine but who will be immediately after) * Common variable immune deficiency or other causes of severe hypogammaglobulinemia requiring chronic treatment with polyvalent immunoglobulin * Malignant tumor under anti-PD1 or anti-PDL1 * People living with HIV * Complicated type 2 diabetes (with micro and / or macroangiopathy) * Group of non-immunocompromised subjects (controls, n = 75) * 60 people vaccinated with the ComirnatyTM * 15 people vaccinated with Astra Zeneca's VaxzevriaTM for the first dose Exclusion Criteria: * Minors * Pregnant or breastfeeding women * Persons under tutorship or curatorship * Protected adults * Person under legal protection * Person not affiliated to a social security scheme * People with a contraindication to receiving the ComirnatyTM vaccine * People who have already been vaccinated against SARS-CoV-2 Note: a history of COVID-19 (\> at 3 months) is not a contraindication to vaccination and is therefore not a criterion for non-inclusion in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS cancer common variable immunodeficiency hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm HIV infectious disease Hypergammaglobulinemia multiple sclerosis neoplasm plasma cell myeloma plasma cell neoplasm polyclonal hypergammaglobulinemia type 2 diabetes mellitus COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Diabetes type 2 Hematologic malignancy HIV Hypergammaglobulinemia Kidney transplant Malignant tumor Multiple sclerosis Myeloma

Contacts and locations

Locations

  • CHU Orléans

    Orléans, 45067, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.